United Therapeutics (NASDAQ:UTHR) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.
Other equities analysts have also issued reports about the stock. UBS Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and reduced their target price for the stock from $115.00 to $94.00 in a research report on Friday, May 17th. They noted that the move was a valuation call. Credit Suisse Group upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $98.00 to $101.00 in a research report on Monday, July 1st. Wedbush reiterated a “buy” rating and set a $273.00 target price on shares of United Therapeutics in a research report on Thursday. LADENBURG THALM/SH SH upgraded shares of United Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $103.00 to $106.00 in a research report on Thursday. Finally, Oppenheimer reduced their target price on shares of United Therapeutics from $160.00 to $155.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. United Therapeutics has a consensus rating of “Hold” and a consensus price target of $123.80.
United Therapeutics stock traded up $0.19 during trading hours on Thursday, hitting $83.26. 445,907 shares of the stock were exchanged, compared to its average volume of 495,083. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $3.47 billion, a PE ratio of 6.22 and a beta of 1.05. United Therapeutics has a 12 month low of $74.31 and a 12 month high of $130.00. The stock has a 50-day moving average of $78.16.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative return on equity of 4.53% and a negative net margin of 7.69%. The firm had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. During the same period in the prior year, the company posted $3.76 earnings per share. United Therapeutics’s quarterly revenue was down 6.8% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics will post -5.03 EPS for the current year.
In related news, Director Richard Giltner sold 5,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $79.05, for a total value of $395,250.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at $395,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Raymond Dwek sold 3,750 shares of the stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $76.11, for a total transaction of $285,412.50. Following the completion of the transaction, the director now owns 3,750 shares in the company, valued at $285,412.50. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Financial Gravity Wealth Inc. acquired a new stake in United Therapeutics in the first quarter worth $46,000. Private Ocean LLC acquired a new stake in United Therapeutics in the second quarter worth $34,000. NEXT Financial Group Inc raised its holdings in United Therapeutics by 72.7% in the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 200 shares during the period. Quadrant Capital Group LLC raised its holdings in United Therapeutics by 552.0% in the first quarter. Quadrant Capital Group LLC now owns 489 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 414 shares during the period. Finally, Signaturefd LLC raised its holdings in United Therapeutics by 42.0% in the first quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 236 shares during the period. Institutional investors and hedge funds own 95.37% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: Insider Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.